Comprehensive M&A data with integrated detailed company information
Takeda selling Shire’s eye care unit: Bloomberg
Posted on Thursday, 13 September 2018 13:27
Japanese pharmaceutical company Takeda could decide to sell Shire’s eye care business once its acquisition of the UK-based biopharmaceuticals player completes, according to Bloomberg, citing people familiar with the matter.
The sources, who did not wish to be identified as the situation is private, said a divestment of the unit could serve to repay some of the debt incurred as a result of the takeover.
Takeda agreed to acquire Shire for GBP 46.00 billion back in May.
Completion is expected to follow during the first half of 2019, subject to the green light from regulatory authorities and shareholders in both companies.
Bloomberg’s sources were quick to caution that Takeda has not yet taken a final decision on whether or not to sell the eye care unit and the possibility is merely under consideration at this stage.
The news provider noted that Shire’s Natpara medicine is another asset which could potentially go on the block.
According to the sources, depending on the operations which are ultimately offloaded, Takeda could raise between USD 4.00 billion and USD 5.00 billion from the divestments.
None of the parties involved have commented on the report at this time.
Should Takeda sell the eye care business, it would not be the first asset it has sought to offload this year; in late March, it agreed to divest Brazilian pharmaceutical research and development firm Multilab Industria e Comercio de Produtos Farmaceuticos to Novamed.
In August of last year, it sold Japanese animal breeding player Takeda Rabics to Hamri.
No financial details of either transaction were disclosed.
According to Zephyr, the M&A database published by Bureau van Dijk, there have been 840 deals targeting pharmaceutical preparation manufacturers announced worldwide since the beginning of 2018.
Of these, the most valuable is Takeda’s Shire takeover, which accounts for 41.5 per cent of the total GBP 110.85 billion-worth of dealmaking signed off in the year to date.
© Zephus Ltd